Form D · Biotechnology
Lung Therapeutics, Inc.
Austin, TX · CIK 0001611241
Offering snapshot reported Apr 4, 2022 · SEC filing
- Reported sold
- $10.1M Offering amount: $15M
- Investors reported
- 213 Form D · investor count
- Minimum accepted
- $15K Reported outside-investor minimum
- First sale
- Mar 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 4, 2022 | Initial | $10,065,000 | No comparison | 213 | SEC filing |
| Oct 31, 2019 | Amendment | $38,682,750 | $37,637,750vs Mar 8, 2016 | 42 | SEC filing |
| May 24, 2019 | Initial | $36,152,750 | No comparison | 38 | SEC filing |
| Jul 26, 2018 | Amendment | $3,855,000 | $2,810,000vs Mar 8, 2016 | 15 | SEC filing |
| Jun 18, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 19, 2017 | Amendment | $14,333,859 | $13,288,859vs Mar 8, 2016 | 17 | SEC filing |
| Feb 24, 2017 | Amendment | $3,476,170 | $2,431,170vs Mar 8, 2016 | 6 | SEC filing |
| Mar 8, 2016 | Initial | $1,045,000 | No comparison | 2 | SEC filing |
| Sep 30, 2015 | Amendment | $2,568,912 | $1,000,000vs Sep 10, 2014 | 3 | SEC filing |
| Sep 10, 2014 | Initial | $1,568,912 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $856K
- Form D file number
- 021-440261
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Newbridge Securities Corporation | 104065 |
Source: Form D, filed Apr 4, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William C. Fairey | Director |
| Aaron G.L. Fletcher | Director |
| Charles Garner | Executive |
| Steven Idell | Director |
| Jim Mervis | Director |
| Robert Mills | Director |
| R. A. Session | Director |
| James Brian Windsor | Director, Executive |
| Brian Windsor | Director, Executive |
| Joseph Woelkers | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3801 S. Capital Of Tx Hwy Suite 330
Austin, TX, 78704
Austin, TX, 78704